Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
FOX | Dividend Discrepancies | 10/04/19 | 6 | 2.9K | |||
|
|||||||
FOX | Ann: Removal from the Official List at close 08/0 | 08/05/14 | 0 | 977 | |||
|
|||||||
FOX | Ann: SEC Form 8-K | 08/05/14 | 0 | 691 | |||
|
|||||||
FOX | Ann: Daily share buy-back notice - Appendix 3E | 07/05/14 | 0 | 638 | |||
|
|||||||
FOX | Ann: Daily share buy-back notice - Appendix 3E | 06/05/14 | 0 | 652 | |||
|
|||||||
FOX | Ann: FOX Share Cancellation | 05/05/14 | 0 | 821 | |||
|
|||||||
FOX | Ann: Appendix 3B | 10:08 | 0 | 488 | |||
|
|||||||
FOX | Ann: Press Release | 09:32 | 0 | 528 | |||
|
See All Discussions